Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience.

Multiple myeloma (MM) represents 1.8% of all new cancer cases in the U.S. While not curable, advances in treatment, including autologous stem cell transplant (ASCT) and maintenance therapy, have dramatically improved progression-free survival (PFS) and overall survival (OS). We performed a retrospective survival analysis on newly diagnosed MM (NDMM) patients receiving ASCT from 1992-2016 at the Ohio State University. A total of 1001 consecutive NDMM patients were eligible. Patients were split into five groups based on historic changes in novel agents for the treatment of MM. Across the years (1992-2016), there was a statistically significant improvement in both PFS ( p < 0.01) and OS ( p < 0.01). Significant improvements in both PFS and OS were seen in patients ≤65 years ( p < 0.001 and p = 0.002) and >65 years old ( p < 0.001 and p = 0.001), respectively. Improved PFS and OS were seen in both standard-risk ( p < 0.001 and p < 0.001) and high-risk patients ( p < 0.001 and p = 0.019). The post-transplant response showed statistically significant improvement across the years ( p < 0.01). Survival rates for NDMM patients have significantly improved primarily due to the inclusion of novel therapies and post-ASCT maintenance.